Community Statement from Genentech on Hemlibra supply amid 2019-nCoV
The World Health Organization (WHO) has declared a Public Health Emergency of International Concern (PHEIC) in response to the 2019-nCoV (novel coronavirus) outbreak. This is a serious health situation and we extend our sympathies to people in the community who have lost or have sick loved ones. We recognize that the public and private sectors across the globe need to work together to help effectively manage this developing situation.
We understand the importance of Hemlibra for people with hemophilia A and are committed to ensuring adequate supply amid queries around how the coronavirus might impact availability of Hemlibra. To date, Hemlibra has been manufactured at Chugai’s sites in Japan. In line with common practice to ensure supply continuity of its medicines, Roche and Genentech are also producing Hemlibra at an alternative site outside of Japan. Our global manufacturing network has robust plans for dealing with the impact of potential health and other global crises.
As of now, we have not identified any critical component that would impact our ability to supply Hemlibra in the future, based on current demand forecasts. Logistics and shipments of Hemlibra are also stable at this point in time.
We are actively assessing and monitoring the situation and any risk of potential impact to our supply chain. Should we become aware of any change to the supply or availability of Hemlibra at any point, we will inform the hemophilia community.
Please refer to our Roche company statement on roche.com for further details on the subject.